EUVIMEDEUVIMED entdecken
Open Access · CC BY-SA 4.0

Alantolactone: A Potential Multitarget Drug candidate for Prevention of SARS-CoV-2 Cell Entry

Erum Zafar, Zainab Ahsan, Muhammad Faisal Maqbool, Aqsa Zaman, Sameena Gul, Amara Maryam, Muhammad Khan, Hafiz Abdullah Shakir, Muhammad Irfan

Journal of Molecular Docking · 2022

DOI: 10.33084/jmd.v2i2.3679 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Molecular Docking, 2022. Verfasst von Erum Zafar und 8 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The novel strain of coronavirus, SARS-CoV-2, has spread adverse effects on human health with high mortality rates worldwide. SARS-CoV-2 is a severe respiratory disease expressed through positive single stranded RNA enveloped virus. SARS-CoV-2 had affected globally and is influencing the economy as well. The rapidly spreading coronavirus infection has discombobulated the researchers in perpetuate search for different or effective therapeutic drugs. Most of the connatural products are proposed to have significant clinical outcomes but their pathways of action are not clear. This molecular docking study presents alantolactone, a bio-active member of sesquiterpene family as a successful inhibitor of SARS-Cov-2 and human receptor proteins. Alantolactone shows high binding affinity with the SARS-CoV-2 target proteins such as spike glycoprotein (S-protein), nucleocapsid protein (N-protein), main protease (MPro), and papain-like protease (PLPro) with a binding affinity of -7.3 kcal/mol, -7.9 kcal/mol, -6.8 kcal/mol, and -7.1 kcal/mol, respectively as well as human receptor proteins associated with the recognition, binding and biogenesis of SARS-CoV-2 such as angiotensin-converting enzyme 2 (ACE-2), receptor binding domain (S1-RBD) and ACE2 interphase, furin, adaptor-associated protein kinase 1 (AAK1), cyclin G-associated kinase (GAK), and both closed and open configurations of the two-pore channel (TPC2) with binding energies of -6.7 kcal/mol, - 6.9 kcal/mol, -8.1 kcal/mol, -7.3 kcal/mol, and -7.9 kcal/mol, respectively. Molecular docking and ADMET properties and toxicity predictions suggest that alantolactone could effectively binds with various viral target protein and human target proteins and could be developed into a novel SARS-coV-2 inhibitor.

Zitieren

APA

Zafar, E., Ahsan, Z., Maqbool, M. F., Zaman, A., Gul, S., Maryam, A., Khan, M., Shakir, H. A., & Irfan, M. (2022). Alantolactone: A Potential Multitarget Drug candidate for Prevention of SARS-CoV-2 Cell Entry. Journal of Molecular Docking. https://doi.org/10.33084/jmd.v2i2.3679

Vancouver

Zafar E, Ahsan Z, Maqbool MF, Zaman A, Gul S, Maryam A, et al. Alantolactone: A Potential Multitarget Drug candidate for Prevention of SARS-CoV-2 Cell Entry. Journal of Molecular Docking. 2022. doi:10.33084/jmd.v2i2.3679

BibTeX
@article{Zafar2022,
  author = {Zafar, Erum and Ahsan, Zainab and Maqbool, Muhammad Faisal and Zaman, Aqsa and Gul, Sameena and Maryam, Amara and Khan, Muhammad and Shakir, Hafiz Abdullah and Irfan, Muhammad},
  title = {Alantolactone: A Potential Multitarget Drug candidate for Prevention of SARS-CoV-2 Cell Entry},
  journal = {Journal of Molecular Docking},
  year = {2022},
  doi = {10.33084/jmd.v2i2.3679}
}
Kostenlos starten →